Open-Label Use of Highly* Purified CBD (Epidiolex®) in Patients With CDKL5 Deficiency Disorder and Aicardi, Dup15q, and Doose Syndromes

Epilepsy and Behavior - United States
doi 10.1016/j.yebeh.2018.05.013
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Efficacy and Safety of Octanorm (Cutaquig®) in Adults With Primary Immunodeficiencies With Predominant Antibody Deficiency: A Prospective, Open-Label Study

Immunotherapy
OncologyAllergyImmunology
2020English

An Open Label Study to Evaluate Safety and Efficacy of Unex® Capsules in Patients With Urinary Disorders

Journal of Ayurveda Medical Sciences
2018English

A Prospective Open-Label Trial of a CBD/THC Cannabis Oil in Dravet Syndrome

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Topiramate Use in Obese Patients With Binge Eating Disorder: An Open Study

Canadian Journal of Psychiatry
PsychiatryMental Health
2002English

Aripiprazole in Children and Adolescents With Tourette's Disorder: An Open-Label Safety and Tolerability Study

Journal of Child and Adolescent Psychopharmacology
Mental HealthChild HealthPharmacologyPerinatologyPsychiatryPediatrics
2009English

A Pilot Open Label Study of Cystoprotek® in Interstitial Cystitis

International Journal of Immunopathology and Pharmacology
AllergyImmunologyPharmacology
2005English

An Open Label Pilot Trial of Abhaya Ghrita in Autistic Disorder

International Journal of Complementary & Alternative Medicine
2018English

158 Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

CNS Spectrums
PsychiatryMental HealthNeurology
2020English

Clinical Experience With Open-Label Topiramate Use in Epileptic Children With CNS Anomalies

Epilepsy and Seizure
Neurology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy